Share This Article:

Development of Oral Dissolving Gelatin Beads Containing Allopurinol for the Prevention and Treatment of Mucositis

Abstract Full-Text HTML Download Download as PDF (Size:464KB) PP. 295-299
DOI: 10.4236/pp.2012.33039    3,821 Downloads   7,714 Views  

ABSTRACT

Oral dissolving gelatin beads (GBs) containing allopurinol (AP) were prepared by the seamless capsule method and their rheological properties were examined. The release profiles of both gelatin and AP from GBs were also investigated in limited dissolution medium. GBs containing AP provided an easy-to-handle dosage form, but the physical strength of the beads immediately decreased upon contact with physiological saline at 37℃. Gelatin was released from the outer layer of GBs in physiological saline, with almost all the gelatin dissolved after 5 min, together with approximately 30% of the AP contained in the inner layer of the GB. The oral administration of GBs likely results in immediate softening of the GB upon contact with saliva. The released AP acts directly at inflammation sites, in a manner similar following oral rinsing with an AP suspension. Therefore, GBs are a useful dosage form for preventing or treating localized problems in the oral cavity, such as mucositis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Y. Murata, T. Isobe, K. Kofuji, M. Mizutani and R. Kamaguchi, "Development of Oral Dissolving Gelatin Beads Containing Allopurinol for the Prevention and Treatment of Mucositis," Pharmacology & Pharmacy, Vol. 3 No. 3, 2012, pp. 295-299. doi: 10.4236/pp.2012.33039.

References

[1] J. Breitkreutz and J. Boos, “Drug Delivery and Formulations,” Handbook of Experimental Pharmacology, Vol. 205, 2011, pp. 91-107.
[2] V. Parkash, S. Maan, Deepika, S. K. Yadav, Hemlata and V. Jogpal, “Fast Disintegrating Tablets: Opportunity in Drug Delivery System,” Journal of Advanced Pharmaceutical Technology & Research, Vol. 2, No. 4, 2011, pp. 223-235.
[3] S. Nalamachu, D. Hassman, M. S. Wallace, S. Dumble, R. Derrick and J. Howell, “Long-Term Effectiveness and Tolerability of Sublingual Fentanyl Orally Disintegrating Tablet for the Treatment of Breakthrough Cancer Pain,” Current Medical Research and Opinion, Vol. 27, No. 3, 2011, pp. 519-530. doi:10.1185/03007995.2010.545380
[4] F. Cilurzo, I. E. Cupone, P. Minghetti, S. Buratti, C. G. Gennari and L. Montanari, “Diclofenac Fast-Dissolving Film: Suppression of Bitterness by a Taste-Sensing System,” Drug Development and Industrial Pharmacy, Vol. 37, No. 3, 2011, pp. 252-259. doi:10.3109/03639045.2010.505928
[5] V. Garsuch and J. Breitkreutz, “Comparative Investigations on Different Polymers for the Preparation of Fast-Dissolving Oral Films,” Journal of Pharmacy and Pharmacology, Vol. 62, No., 2010, pp. 539-545.
[6] R. C. Rossi, C. L. Dias, E. M. Donato, L. A. Martins, A. M. Bergold and P. E. Fr?ehlich, “Development and Validation of Dissolution Test for Ritonavir Soft Gelatin Capsules Based on in Vivo Data,” International Journal of Pharmaceutics, Vol. 338, No. 1-2, 2007, pp. 119-124. doi:10.1016/j.ijpharm.2007.01.036
[7] J. R. Zuniga, R. J. Noveck, W. K. Schmidt, S. E. Boesing and E. V. Hersh, “Onset of Action of Diclofenac Potassium Liquid-Filled Capsules in Dental Surgery Patients,” Current Medical Research and Opinion, Vol. 27, No. 9, 2011, pp. 1733-1739. doi:10.1185/03007995.2011.600300
[8] G. Carlomagno, S. De Grazia, V. Unfer and F. Manna, “Myo-Inositol in a New Pharmaceutical Form: A Step forward to a Broader Clinical Use,” Expert Opinion on Drug Delivery, Epub ahead of Print (2012). doi:10.1517/17425247.2012.662953
[9] R. P. Gullapalli, “Soft Gelatin Capsules (Softgels),” Journal of Pharmaceutical Sciences, Vol. 99, No. 10, 2010, pp. 4107-4148. doi:10.1002/jps.22151
[10] K. Taki, F. Takayama and T. Niwa, “Beneficial Effects of Bifidobacteria in a Gastrore-sistant Seamless Capsule on Hyperhomocysteinemia in Hemodialysis Patients,” Journal of Renal Nutrition, Vol. 15, No. 1, 2005, pp. 77-80. doi:10.1053/j.jrn.2004.09.028
[11] D. M. Keefe, M. M. Schubert, L. S. Elting, S. T. Sonis, J. B. Epstein, J. E. Raber-Durlacher, C. A. Migliorati, D. B. McGuire, R. D. Hutchins and D. E. Peterson, “Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis,” Cancer, Vol. 109, No. 5, 2007, pp. 820-831. doi:10.1002/cncr.22484
[12] H. Dozono, M. Murakami, T. Watanabe, Y. Nagata, K. Nakamura, M. Ishibashi and K. Yokoi, “The Prevention of Stomatitis Induced by Anti-Cancer Drugs,” Gan to Kagaku Ryoho, Vol. 17, 1990, pp. 931-933.
[13] M. Asada, R. Kamaguchi, T. Ohno, T. Kozaki and T. Sugimoto, “Seamless Capsule Entrapped Living Microorganisms,” Seibutsu-kogaku, Vol. 87, No. 3, 2009, pp. 123-128.
[14] M. K. Reinders, L. C. Nijdam, E. N. van Roon, K. L. Movig, T. L. Jansen, M. A. van de Laar and J. Brouwers, “A Simple Method for Quantification of Allopurinol and Oxipurinol in Human Serum by High-Performance Liquid Chromatography with UV-Detection,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 45, No. 2, 2007, pp. 312-317. doi:10.1016/j.jpba.2007.08.002
[15] C. Dawes, “Physio-logical Factors Affecting Salivary Flow Rate, Oral Sugar Clearance, and the Sensation of Dry Mouth in Man,” Journal of Dental Research, Vol. 66, 1987, pp. 648-653.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.